INTRODUCTION
============

Skeletal muscle is one of the major target organs of insulin action and the primary site for insulin-mediated glucose uptake in the postprandial state \[[@B1]-[@B4]\]. In addition, reduced muscle mass could potentially induce hyperglycemia and insulin resistance \[[@B5]\]. Therefore, skeletal muscle could be an original target for the treatment of metabolic disorders, e.g., insulin resistance, glucose intolerance, and type 2 diabetes mellitus \[[@B3]\]. In elderly patients with diabetes, dietary amino acid supplements could antagonize muscle catabolism and glucose derangement, and have been shown to increase insulin sensitivity and decrease glycated hemoglobin (HbA1c) levels \[[@B5]\]. Serum creatinine is a breakdown product of creatine phosphate in muscle. Since the amount of creatinine per unit of skeletal muscle mass is consistent and the breakdown rate of creatine is also consistent, plasma creatinine concentration is very stable and is a direct reflection of skeletal muscle mass \[[@B4],[@B6]\]. In the Kansai Healthcare Study, lower serum creatinine levels demonstrated an association with an increased risk of type 2 diabetes \[[@B4]\]. A lower volume of skeletal muscle could mean fewer target sites for insulin action and this, in part, may explain the pathogenesis of type 2 diabetes associated with lower serum creatinine \[[@B4]\]. Accordingly, we attempted to determine whether serum creatinine and its variation are related to development of type 2 diabetes, along with other risk factors for diabetes.

METHODS
=======

This study was conducted retrospectively. Subjects included 2,676 nondiabetic patients aged 18 to 75 years who visited the health care center of Yeungnam University Medical Center between 2001 January 1 and 2003 December 31. These subjects were visited again from 2005 January 1 to 2008 December 31. The presence of diabetes was determined by fasting plasma glucose (FPG) ≥7.0 mmol/L (*n*=61), HbA1c ≥6.5% (*n*=15), history of diabetes, or taking antidiabetic agents, which was ascertained via questionnaire; subjects with diabetes at baseline were excluded (*n*=20) \[[@B7]\]. We attempted to evaluate the serum creatinine as a surrogate marker of muscle mass under normal and stable renal function. Estimated glomerular filtration rate (eGFR) was calculated from creatinine using the Modification of Diet in Renal Disease (MDRD) equation, as follows: eGFR=186.3×\[serum creatinine (mg/dL)\]-1.154×\[age (years)\]-0.203×(0.742 if female) \[[@B8]\]. We included chronic kidney disease stage 1 and 2 (eGFR ≥60 mL/min/1.73 m^2^), and excluded subjects with higher serum creatinine (≥132.6 µmol/L, *n*=5) or eGFR \<60 mL/min/1.73 m^2^ (*n*=49) at baseline. Blood samples were collected after an overnight fast (at least 8 hours) at baseline and at the end of the follow-up. Serum creatinine and other routine laboratory blood tests were performed with an automatic Olymphus AU5400 Analyzer (Olympus Optical, Tokyo, Japan). Serum creatinine was calibrated using the Jaffe method installed on the Olymphus AU5400 Analyzer. A variation of serum creatinine (ΔCre) was defined as a difference between follow-up and baseline creatinine. FPG was measured using the hexokinase method. HbA1c was measured using high performance liquid chromatography (HLC-723G7, Tosoh, Tokyo, Japan). Serum total cholesterol was measured using an enzymatic colorimetric method (Kyowa Medex Co., Ltd., Tokyo, Japan). Serum high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol was measured using a direct enzymatic assay (Kyowa Medex Co., Ltd.). Body mass index (BMI) was computed from measurements of height and weight, as follows: BMI=body weight (kg)/height (m^2^). In some subjects, we analyzed body composition using the Inbody 720 (Biospace, Seoul, Korea), a multifrequency impedance body composition analyzer. The Inbody 720 uses an 8-point tactile electrode method, measuring resistance at five specific frequencies (1, 50, 250, 500 kHz, and 1 MHz) and reactance at three specific frequencies (5, 50, and 250 kHz).

Differences of continuous variables between subjects who were diagnosed with new-onset diabetes and the no diabetes group were analyzed using Student *t* test for statistical analysis. We used linear regression analysis to evaluate correlation between serum creatinine, muscle mass, and percentage of body fat tissue. We used multiple logistic regression analysis and computed odds ratios (ORs) for the incidence of type 2 diabetes in order to determine the relationship between the incidence of type 2 diabetes and variation of serum creatinine. Results were expressed as a mean±SD for continuous variables. Statistical analyses were performed using SPSS version 18.0 for Windows (IBM Co., Armonk, NY, USA). All statistical tests were two tailed and a *P* value of less than 0.05 was regarded as statistically significant. All patients provided informed consent, and the study protocol was approved by our local ethics committee, as well as the Institutional Review Board of Yeungnam University Medical Center.

RESULTS
=======

A total of 2,602 nondiabetic subjects were finally included in this study and the mean follow-up duration was 4.5±0.67 years. During the follow-up period, 106 subjects were diagnosed with diabetes and were categorized into the new-onset diabetes group. A summary of the baseline characteristics of the subjects is shown in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}. Compared with the no diabetes group, subjects in the new-onset diabetes group were older, with higher BMI, higher systolic blood pressure (SBP)/diastolic blood pressures (DBP), higher FPG, and higher HbA1c levels (*P*\<0.05). The baseline serum creatinine level did not differ between the two groups, however, ΔCre was lower in the new-onset diabetes group compared with the no diabetes group (*P*\<0.05). [Table 2](#T2){ref-type="table"} shows the differences in characteristics of subjects in the negative ΔCre group (ΔCre \<0) and positive ΔCre group (ΔCre ≥0). Subjects in the negative ΔCre group (*n*=755) had higher BMI and SBP. No difference in the baseline fasting blood glucose and HbA1c was observed between the two groups. However, more patients in the negative ΔCre group developed type 2 diabetes (*P*\<0.05).

In multivariate regression analysis ([Table 3](#T3){ref-type="table"}), higher SBP, FPG, HbA1c, and lower HDL-C showed an association with development of type 2 diabetes (*P*\<0.05). After adjusting for age, gender, BMI, SBP and DBP, FPG, HbA1c, triglyceride, HDL-C, and γ-GTP, the decrease of serum creatinine showed an independent association with development of type 2 diabetes with an OR of 1.885 (95% confidence interval \[CI\], 1.127 to 3.153; *P*=0.015). In male subjects (*n*=1,551), the OR of negative ΔCre was 2.249 (95% CI, 1.184 to 4.274; *P*=0.013).

In subgroup analysis using bioelectric impedance analysis (BIA) method, we obtained the lean body mass of 1,067 subjects at baseline and 27 cases were identified as newly diagnosed diabetes. Serum creatinine showed positive correlation with body muscle mass and lean body mass, and negative correlation with body fat percentage in linear regression analysis ([Fig. 1](#F1){ref-type="fig"}). Although basal lean body mass was not associated with the risk for incident diabetes, the change of lean body mass was negatively correlated with incident diabetes (*P*\<0.05). The change of lean body mass was also positively correlated with the change of serum creatinine (*P*\<0.05). Serum creatinine was negatively correlated with body fat mass and percent body fat (*P*\<0.05). ΔCre and the change of body fat mass showed marginal correlation, but had no statistical significance (*P*=0.05).

DISCUSSION
==========

In this retrospective follow-up study, we found that the variation of serum creatinine is closely associated with age-related sarcopenic changes. Additionally negative ΔCre, that is decreased creatinine, is independent risk factor of diabetes in healthy subjects with normal renal function.

Reduced muscle mass, or sarcopenia, has been reported as a well-known risk factor for insulin resistance and type 2 diabetes \[[@B9]-[@B12]\]. Since skeletal muscle is the primary tissue contributing to whole body insulin-mediated glucose disposal, sarcopenia may be an important causal factor in age-induced insulin resistance and type 2 diabetes susceptibility \[[@B9]\]. In the study reported by Srikanthan and Karlamangla \[[@B13]\], muscle mass relative to body size might also predict the level of insulin resistance and risk of prediabetes. They also revealed that sarcopenia might be an early predictor of diabetes susceptibility independent of obesity in a large population study \[[@B9]\]. Kim et al. \[[@B14]\] reported that sarcopenic obesity was associated with the risk of metabolic syndrome in a cohort study of Korean subjects. Similarly, Lim et al. \[[@B15]\] showed that sarcopenic obesity was more closely correlated with metabolic syndrome than either sarcopenia or obesity alone. Therefore, serial examinations about sarcopenic and obese changes, through analyzing proportions of skeletal muscles and body fat, are presumed to predict diabetes. However, there are some limitations for carrying those predictions into clinical practice. What the gold standard is still debatable among various instruments to measure muscle mass, strength, and function. Although dual energy X-ray absorptiometry (DEXA) or computed tomography were currently accepted to be gold standard tests for evaluating body composition \[[@B16]\], these methods are not easily accessible and not commonly available to large epidemiologic studies due to time and cost. Additionally, there is not a consensus about concepts of sarcopenia and sarcopenic obesity, and it is unclear which definition is most powerful to predict prognosis \[[@B17]\]. Recently the European Working Group on Sarcopenia in Older People suggested a practical definition using the concepts of muscle mass and function \[[@B18]\], but that also has limitations. This criteria is not accepted widely, and inappropriate to apply other ethnicities, including Asians.

We hypothesized that variation of serum creatinine might be related to change of insulin sensitivity, and predict the risk of type 2 diabetes. Serum creatinine concentration is simple, cheap, and widely used for evaluation of renal function, and is known to be a very stable surrogate marker of skeletal muscle mass \[[@B4],[@B6],[@B19]\]. Previous studies have reported correlations of total plasma creatinine with lean body mass, estimated anthropometrically using BIA or DEXA \[[@B20]-[@B22]\]. According to Harita et al. \[[@B4]\], lower serum creatinine increased the risk of type 2 diabetes in their large cohort study. In a large cohort study of chronic kidney disease patients receiving hemodialysis, an increase in lean body mass accompanied by a parallel increase in muscle mass was associated with survival benefit \[[@B23]\]. Consistent with these results, we found that serum creatinine was positively associated with muscle mass and had inverse relationship with percentage of body fat in subgroup analysis using BIA. The variation of serum creatinine also may imply the change of lean body mass, as we expected. The incidence of type 2 diabetes was higher in the negative ΔCre group, even though the baseline creatinine level did not differ between the groups. Taken together, subjects with similar creatinine level at baseline may have different risk of diabetes and negative ΔCre is also considered to independent risk factor of diabetes. Serial follow-up of serum creatinine could be alternative for repetitive body composition analysis.

Oterdoom and his colleagues \[[@B24]\] demonstrated that low muscle mass, as reflected by low creatinine excretion, was associated with major adverse cardiovascular events and all cause mortality in general populations. They reported that their results were independent of insulin sensitivity, components of the metabolic syndrome, and inflammation. However, muscle mass measured by urinary creatinine excretion was positively associated with fasting insulin and components of metabolic syndrome. Also, diabetes was not associated with lower creatinine excretion in both male and female subjects. The authors explained that insulin is an anabolic hormone, so subjects with higher muscle masses may have higher insulin concentrations. When comparing our results, the discrepancies might be come from differing methods to assess muscle mass (urinary creatinine excretion vs. serum creatinine level), but further studies are needed to clarify the differences in results.

Female gender tended to have lower skeletal muscle mass than male. Intuitionally, gender differences might be considered when using serum creatinine as a surrogate marker of muscle mass. A large cohort study of Japanese men \[[@B4]\] reported that low serum creatinine increased the risk of type 2 diabetes, but the investigators did not include females. They suggested the results may differ in women because of their lower levels of skeletal muscle mass. Serum creatinine, as a risk factor of diabetes, was more closely associated in male than females in our study. These findings suggest that variation of creatinine can differ depending on gender, and gender differences should be considered and weighed practically.

Our study had several limitations. Firstly, given that serum creatinine closely related with skeletal muscle mass, it could be influenced by numerous factors such as drugs and other dietary factors. We tried to eliminate confounding factors through questionnaires at baseline, but could not exclude exogenous factors during follow-up periods. Secondly, this was a retrospective observational study and the numbers of participants were relatively small for single center recruitment. Thirdly, some cases of undetermined diabetes might have existed since postprandial plasma glucose levels and 75 g oral glucose tolerance tests were not checked. Additionally, the variation of creatinine could be surrogate of insulin resistance but not reflect insulin secretory function, so β-cell failure-another main cause of diabetes-was overlooked. We did not check C-peptide or islet cell autoantibodies, so it is difficult to predict occurrence of diabetes by progressive β-cell failure, such as late adult onset of diabetes. Finally, direct comparisons between insulin resistance indexes (i.e., homeostasis model assessment-estimated insulin resistance, quantitative insulin sensitivity check index, etc.) and creatinine level were not conducted in our subjects.

In summary, the results of this study showed that serum creatinine could be used as a surrogate marker of skeletal muscle mass, and the decrease of serum creatinine over time might be regarded as a risk factor for type 2 diabetes. Therefore, monitoring of serum creatinine can be helpful in prediction and assessment of type 2 diabetes risk. In order to determine and confirm these results, large-scale prospective randomized controlled trials will be needed in the future.
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Characteristics according to Development Status of Type 2 Diabetes during Follow-Up
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Values are expressed as mean±SD or number (%).

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose level; HbA1c, glycated hemoglobin; ΔCre, follow-up serum creatinine level to baseline serum creatinine level; Decreased Cre, follow-up serum creatinine level to baseline serum creatinine level \<0; BUN, blood urea nitrogen; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γ-GTP, γ-glutamyl transpeptidase; hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate.

^a^*P*\<0.05.
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Characteristics according to the Difference of Serum Creatinine between Baseline and Follow-Up Period
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Values are expressed as mean±SD or number (%).

ΔCre, follow-up serum creatinine level to baseline serum creatinine level; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose level; HbA1c, glycated hemoglobin; BUN, blood urea nitrogen; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γ-GTP, γ-glutamyl transpeptidase; hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate.

^a^*P*\<0.05.
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Risk Factors Associated with Development of Type 2 Diabetes
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OR and *P* value analyzed by multivariate regression analysis adjusted for age, sex, BMI, SBP, FPG, HbA1c, TG, HDL-C, and γ-GTP.

OR, odds ratio; CI, confidence interval; ΔCre, follow-up serum creatinine level to baseline serum creatinine level; BMI, body mass index; SBP, systolic blood pressure; FPG, fasting plasma glucose level; HbA1c, glycated hemoglobin; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; γ-GTP, γ-glutamyl transpeptidase.
